Samsung Bioepis is a joint venture between Samsung Biologics (85%) and the U.S.-based Biogen Idec (15%).[120] In 2014, Biogen Idec agreed to commercialize future anti-TNF biosimilar products in Europe through Samsung Bioepis.[121]